ADI-001 demonstrated 71% overall response rate (ORR) and 63% complete response (CR) rate across all dose levels in patients with median 4 prior lines of therapy; 50% of patients enrolled had previously progressed on anti-CD19 chimeric antigen receptor T cell (CAR T) therapy
83% ORR and 67% CR rate observed in heavily pre-treated patients who had progressed on prior CAR T
Six-month CR rate consistent with autologous CAR T cell therapy
Favorable safety with no significant incidence of CRS (cytokine release syndrome) or ICANS (immune effector cell associated neurotoxicity syndrome)
Robust pharmacokinetic profile in dose level 4 (DL4) with Cmax and Day 28 persistence exceeding approved CD19 autologous CAR T therapy
Plan to transition ADI-001 program into potentially pivotal Phase 2 study in post-CAR T large B-cell lymphoma (LBCL) patients in first half of 2024
Clinical update from additional post-CAR T LBCL patients expected in second half of 2024
Company to host investor webcast on Monday, June 26 at 4:30pm ET